Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An expanded access program of BICX104 (implantable naltrexone pellet) for the treatment of opioid use disorder (OUD) patients

Next Previous
X
Search
Trial Profile

An expanded access program of BICX104 (implantable naltrexone pellet) for the treatment of opioid use disorder (OUD) patients

Status: Planning
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 18 Aug 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naltrexone (Primary)
  • Indications Opioid-related disorders
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Sponsors BioCorRx

    • Most Recent Events

    • 18 Aug 2023 New trial record
    • 15 Aug 2023 According to BioCorRx media release, the company announced the submission of expanded access protocol to US Food and Drug Administration (FDA).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top